Baseline findings of a multicentric ambispective cohort study (2021–2022) among hospitalised mucormycosis patients in India

References

• Arun AB, Hasan MM, Rackimuthu S, Ullah I, Mir T, Saha A. 2022. Antifungal drug shortage in India amid an increase in invasive fungal functions during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 43(12):1965–1966. doi: 10.1017/ice.2021.426.
   PubMed Web of Science ®Google Scholar
• Chander J, Kaur M, Singla N, Punia RPS, Singal SK, Attri AK, Alastruey-Izquierdo A, Stchigel A, Cano-Lira J, Guarro J, et al. 2018. Mucormycosis: Battle with the deadly enemy over a five-year period in India. J Fungi. 4(2):46. doi:10.3390/jof4020046.
   Web of Science ®Google Scholar
• Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Chen SA, Kong DCM. 2019a. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. Int J Antimicrob Agents. 53(5):589–597. doi: 10.1016/j.ijantimicag.2019.01.002.
   PubMed Web of Science ®Google Scholar
• Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, Chen SA. 2019b. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect. 25(1):26–34. doi: 10.1016/j.cmi.2018.07.011.
   PubMed Web of Science ®Google Scholar
• Jeong SJ, Lee JU, Song YG, Lee KH, Lee MJ. 2015. Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis. Mycoses. 58(12):746–752. doi: 10.1111/myc.12428.
   PubMed Web of Science ®Google Scholar
• Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. 2021. Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int J Surg Case Rep. 82:82. doi: 10.1016/2Fj.ijscr.2021.105957.
   Web of Science ®Google Scholar
• Manesh A, John AO, Mathew B, Varghese L, Rupa V, Zachariah A, Varghese GM. 2016. Posaconazole: An emerging therapeutic option for invasive rhino‐orbito‐cerebral mucormycosis. Mycoses. 59(12):765–772. doi: 10.1111/myc.12529.
   PubMed Web of Science ®Google Scholar
• Manesh A, Rupali P, Sullivan MO, Mohanraj P, Rupa V, George B, Michael JS. 2019. Mucormycosis-A clinicoepidemiological review of cases over 10 years. Mycoses. 62(4):391–398. doi: 10.1111/myc.12897.
   PubMed Web of Science ®Google Scholar
• Muthu V, Agarwal R, Rudramurthy SM, Thangaraju D, Shevkani MR, Patel AK, Shastri PS, Tayade A, Bhandari S, Gella V, et al. 2023. Multicenter case–control study of COVID-19–associated mucormycosis outbreak, India. Emerg Infect Dis. 29(1):8–19. doi:10.3201/eid2901.220926.
   Web of Science ®Google Scholar
• Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, Savio J, Sethuraman N, Madan S, Shastri P, et al. 2021. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 27(9):2349–2359. doi:10.3201/eid2709.210934.
   Web of Science ®Google Scholar
• Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, Singh R, Shastri P, Umabala P, Sardana R, et al. 2020. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 26(7):944.e9–944.e15. doi:10.1016/j.cmi.2019.11.021.
   Web of Science ®Google Scholar
• Peterson KL, Wang M, Canalis RF, Abemayor E. 1997. Rhinocerebral mucormycosis: Evolution of the disease and treatment options. Laryngoscope. 107(7):855–862. doi: 10.1097/00005537-199707000-00004.
   PubMed Web of Science ®Google Scholar
• Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. 2012. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 54(1):S23–S34. doi: 10.1093/cid/cir866.
   Google Scholar
• Ponnaiah M, Ganesan S, Bhatnagar T, Thulasingam M, Majella MG, Karuppiah M, Rizwan SA, Alexander A, Sarkar S, Kar SS, et al. 2022. Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India. PloS One. 17(8):e0272042. doi:10.1371/journal.pone.0272042.
   PubMed Web of Science ®Google Scholar
• Prakash H, Chakrabarti A. 2019. Global epidemiology of mucormycosis. J Fungi. 5(1):26. doi: 10.3390/jof5010026.
   Web of Science ®Google Scholar
• Prakash H, Chakrabarti A. 2021. Epidemiology of mucormycosis in India. Microorganisms. 9(3):523. doi: 10.3390/microorganisms9030523.
   PubMed Web of Science ®Google Scholar
• Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, Umabala P, Jillwin J, Varma S, Das A, et al. 2019. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 57(4):395–402. doi:10.1093/mmy/myy060.
   PubMed Web of Science ®Google Scholar
• Reid G, Lynch JP III, Fishbein MC, Clark NM. 2020. Mucormycosis. Semin Respir Crit Care Med. 41(1):99–114. doi: 10.1055/s-0039-3401992.
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, et al. 2005. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 41(5):634–653. doi:10.1086/432579.
   PubMed Web of Science ®Google Scholar
• Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, Singer BH, Galvani AP. 2021. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proc Natl Acad Sci. 118(34):e2109229118. doi: 10.1073/pnas.2109229118.
   PubMed Web of Science ®Google Scholar
• Samarasekera U. 2021. India grapples with second wave of Covid-19. Lancet Microbe. 2(6):e238. doi: 10.1016/S2666-5247(21)00123-3.
   PubMedGoogle Scholar
• Satish D, Joy D, Ross A. 2021. Mucormycosis coinfection associated with global Covid-19. A case-series from India. Int J Otorhinolaryngol Head Neck Surg. 7(5):815–820. doi: 10.18203/issn.2454-5929.ijohns20211574.
   Google Scholar
• Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, Sharma M, Sachdev M, Grover AK, Surve A, et al. 2021. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO study on mucormycosis in India (COSMIC), report 1. Indian J Ophthalmol. 69(7):1670˗1692. doi: 10.4103/2Fijo.IJO_1565_21.
   Web of Science ®Google Scholar
• Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. 2021. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J Laryngol Otol. 135(5):442–447. doi: 10.1017/s0022215121000992.
   Web of Science ®Google Scholar
• Singh AK, Singh R, Joshi SR, Misra A. 2021. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev. 15(4):102146. doi: 10.1016/j.dsx.2021.05.019.
   PubMed Web of Science ®Google Scholar
• Singh J, Yadav AK, Pakhare A, Kulkarni P, Lokhande L, Soni P, Dadheech M, Gupta P, Masarkar N, Maurya AK, et al. 2021. Comparative analysis of the diagnostic performance of five commercial COVID-19 qRT PCR kits used in India. Sci Rep. 11(1):22013. doi: 10.1038/s41598-021-00852-z.
   PubMed Web of Science ®Google Scholar
• Skiada AP, Drogari-Apiranthitou I, Drogari-Apiranthitou M. 2020. Epidemiology and diagnosis of mucormycosis: An update. J Fungi. 6(4):265. doi: 10.3390/jof6040265.
   Web of Science ®Google Scholar
• Sridhara SR, Paragache G, Panda NK, Chakrabarti A. 2005. Mucormycosis in immunocompetent individuals: An increasing trend. J Otolaryngol. 34(6):402–406. doi: 10.2310/7070.2005.34607.
   PubMedGoogle Scholar
• World Health Organization. 2023. Mucormycosis key facts. [accessed 2023 Oct 5]. https://www.who.int/india/home/emergencies/coronavirus-disease-(covid-19)/mucormycosis#:~:text=Mucormycosis%20is%20an%20aggressive%2C%20life,of%20antifungal%20medications%20and%20surgery
   Google Scholar